Former CSPC Pharmaceutical Group Executive President He Yongjiang Departs to Launch New Biotech Venture
CSPC
Innovative Drug Research and Development, Manufacturer
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
Information disclosed by AiQiCha shows that Shanghai Huisibo Biopharmaceutical Technology Co., Ltd. was established on April 13, 2026, with a registered capital of 5 million yuan, and its registered address is located in Qingpu District, Shanghai.From a timeline perspective, this means that after Dr. Hei Yongjiang concluded his term at CSPC, he officially embarked on a new phase of personal entrepreneurship and industry layout.Combined with his nearly three-decade career history, this entrepreneurial endeavor is also seen by the industry as another strategic shift after long-term accumulation.
Dr. Hei Yongjiang is a senior medical expert in China's oncology innovation drug field, with rare experience in global operations of multinational pharmaceutical enterprises and the local practical capabilities of Chinese Biotech. His career trajectory almost spans the entire process of China's innovative drug industry moving from "following" to "global competition." For a long time, he has been deeply involved in the clinical development and medical affairs management of oncology innovation drugs, possessing rich experience in multiple technical pathways such as small molecules, large molecules, biologics, and ADCs. He has particularly accumulated profound expertise in global multicenter clinical trial management, international registration submissions, and strategic R&D pipeline planning.
He Yongjiang graduated fromShihezi Medical CollegeMajoring in Clinical Medicine, obtained a Bachelor of Medicine degree; subsequently enteredWest China University of Medical SciencesMaster of Pharmacology; obtained in 1993University of British ColumbiaA Ph.D. in Pharmacology. His medical and pharmacological education background, which spans both Chinese and Western systems, has also laid a solid foundation for his subsequent international career development.
From 1995 to 2006, Dr. Hei Yongjiang entered the global large multinational pharmaceutical enterprise system, starting his career in clinical development of oncology drugs, and successively worked atBristol-Myers Squibb、RocheAndNovartisInternational pharmaceutical companies such as, and held core positions such as Medical Director of Roche USA and Senior Global Brand Medical Director of Novartis Oncology. During this period, he was deeply involved in the formulation of global clinical strategies for oncology drugs, medical affairs management, and international market collaboration, accumulating systematic international R&D and commercialization experience.
From 2006 to 2015, it was an important accumulation stage in his career. Heiyongjiang joinedAmgenLater, he held key positions such as Executive Medical Director of Global Development and Medical Affairs for Oncology, and Head of Medical Affairs at Amgen China. During his time at Amgen, he led or was deeply involved in the global clinical development and commercialization strategy formulation for major oncology drugs like Motesanib and Vectibix. He was also stationed in China, where he was responsible for building Amgen China's clinical medical team and localized R&D system from the ground up. At the same time, he participated in supporting the company’s submission of multiple registration documents to the FDA, EMA, and Chinese regulatory authorities, playing a significant role in advancing the establishment of multinational pharmaceutical companies' clinical systems in China.
After 2015, Dr. Hei Yongjiang began transitioning from traditional MNCs to innovative pharmaceutical companies. From 2015 to 2018, he served in the United States.AmbrxChief Medical Officer, Focusing on ADC and Bispecific Antibody Fields.During the "blue ocean period" when ADC and bispecific antibodies had not yet gained significant attention, he had already led his team to take the lead in advancing the clinical development and strategic layout of related pipelines.
After returning to China in 2018,Hei Yongjiang has held core management positions in several Chinese innovative drug companies.. Briefly served asQilu PharmaceuticalChief Medical OfficerLater, joined in August 2018.Zai LabServe as CMO, and is fully responsible for the clinical development strategy in the field of oncology. During his tenure, several innovative drug projects of Zai Lab have been accelerated, and the company's overall R&D system and international capabilities have also been further enhanced.
In 2021, Yongjiang Hei joinedYuheng BioCEO and Director, starting to extend from a pure medical R&D role to corporate strategy and business management, leading the formulation of the company's long-term development strategy, and promoting the layout in the field of tumor immunotherapy. In October of the same year, he also joinedWuxi Zhikang Hongyi Biotechnology Co., Ltd.Serve as Co-CEO, focusing on BIC/FIC innovative drug development in the oncology and nephrology fields, advancing multiple ADC products into clinical stages in both China and the U.S., while actively exploring overseas collaborations and global commercialization pathways.
By the end of 2024, Dr. Hei Yongjiang officially joinedCSPC, serving as the Executive President and Global Chief Medical Officer, fully responsible for the group's clinical development of innovative oncology drugs and the construction of medical affairs systems. At the critical stage when CSPC PHARMACEUTICAL GROUP LIMITED is promoting innovation transformation and strengthening its oncology R&D pipeline, his joining was once regarded by the industry as an important signal of CSPC enhancing its international capabilities in innovative drugs.
Now, with the establishment of Shanghai Huisibo Biopharmaceutical Technology Co., Ltd., Dr. Hei Yongjiang has once again embarked on a new entrepreneurial journey. With his extensive experience in global drug development, management background in multinational pharmaceutical companies, and deep understanding of cutting-edge fields such as ADC, it remains to be seen whether Hei Yongjiang’s new platform will achieve a breakthrough in China's innovative drug ecosystem, which is certainly worth continued attention from the industry.
Source: PharmaResearch.net
Click "Yao Du" below”, follow more exciting content
Disclaimer
The push rules of WeChat Official Accounts have changed again. If you don't tap"Views"Or not set to"Star Mark", we might just dissipate in the vast sea of literature~ Click here, don't miss out on the latest news from PharmaDJ!??